RecruitingNot ApplicableNCT07161635

Post Market Clinical Evaluation of Clareon PanOptix Pro and Clareon PanOptix Pro Toric IOLs


Sponsor

Alcon Research

Enrollment

120 participants

Start Date

Oct 14, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this study is to collect safety and performance data on two approved intraocular lenses (IOLs). This study will be conducted in participants who require cataract surgery in both eyes. The IOLs are designed to provide vision at far, arm's length, and near.


Eligibility

Min Age: 22 Years

Inclusion Criteria3

  • Subjects with cataracts in both eyes, planned for removal by routine surgery (phacoemulsification);
  • Subject must be able to understand and sign an approved informed consent form;
  • Subject is willing to complete all the required study visits for the duration of the study;

Exclusion Criteria3

  • Ocular conditions as specified in the protocol;
  • Subjects who desire monovision correction;
  • Previous intraocular or corneal surgery;

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEClareon PanOptix Pro/Pro Toric Trifocal IOL

Intraocular lens (IOL) placed into the lens capsule of the eye during cataract surgery. IOLs are implantable medical devices intended for long-term use over the lifetime of the pseudophakic subject.

PROCEDUREPhacoemulsification

Cataract surgery technique that uses ultrasound to break up and remove the clouded lens, allowing for IOL implantation.


Locations(5)

Wolstan & Goldberg Eye Associates

Torrance, California, United States

Moyes Eye Center

Kansas City, Missouri, United States

Carolina Eyecare Physicians LLC

Mt. Pleasant, South Carolina, United States

Houston Eye Associates

Houston, Texas, United States

The Eye Institute of Utah

Salt Lake City, Utah, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07161635


Related Trials